GSK developed the triavement of chronic obstructive pulmonary disease Trelegy Ellipta approved by the National Drug Administration for listing
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, GSK developed the chronic obstructive pulmonary disease (COPD) tri-therapy fluorobutikason ume bromoquine Verantro inhalation powder mist agent (Trelegy Ellipta) approved by the State Drug Administration for listingTrelegy Ellipta, which was first approved by theFDA(http://for the maintenance treatment of chronic obstructive pulmonary disease on September 18, 2017, is the world's first triple therapy with only one-time-a-day treatment, with global sales of 156 million pounds in 2018June 2018, GSK'sProduct(http://was placed on the market in China and included in the priority review in September 2018This triamcinolone is composed of the acetate fluorobutiasone and ummector, in which the acetate fluorobuticardasone is asynthetic(http://of trifluoroglucocorticoids, with strong anti-inflammatory ability, umimenteramin is a long-acting choline receptor inhibitor, and Verantero is a beta long-acting 2 epinephrine receptor agonist, which can provide a 24-hour long-lasting bronchitracive effectA phase III IMPACT study involving 10,355 COPD patients demonstrated that Trelegy Ellipta had a better effect on reducing acute exacerbation in patients with high-risk slow-resistor lung disease with an acute aggravation history than the second-in-line therapy Relvar/Breo Ellipta and Anoropta (Olehin)at week 52, the annual incidence of moderate to severe acute exacerbation decreased by 15% and 25% respectively during treatment to reach the main endpoint
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
